Search

Your search keyword '"Goldman, M."' showing total 27 results
Start Over Author "Goldman, M." Journal biological psychiatry
27 results on '"Goldman, M."'

22. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia.

Author

Josiassen RC, Goldman M, Jessani M, Shaughnessy RA, Albazzaz A, Lee J, Ouyang J, Orlandi C, and Czerwiec F

Subjects
Adult, Analysis of Variance, Area Under Curve, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Hyponatremia epidemiology, Male, Middle Aged, Schizophrenia epidemiology, Time Factors, Tolvaptan, Antidiuretic Hormone Receptor Antagonists, Benzazepines therapeutic use, Hyponatremia drug therapy, Schizophrenia drug therapy
Abstract

Objectives: Hyponatremia (serum sodium [Na+] concentration <136 mmol/L) is a prevalent and potentially life-threatening medical comorbidity for schizophrenic patients. No definitive pharmacological treatments have been established. Tolvaptan (OPC-41061), an oral non-peptide V2-receptor antagonist, was recently shown to correct hyponatremia in a diverse population of 448 hyponatremic patients. Efficacy in a sub-set of 19 schizophrenic patients with idiopathic hyponatremia included in that sample is specifically examined., Methods: Nineteen subjects were randomly assigned to receive placebo (n = 12) or tolvaptan (n = 7) once daily for 30 days. Dosage adjustment was based on serum Na+ changes, initially 15 mg, titratable to 30 or 60 mg. The average daily area under the curve (AUC) changes in serum Na+ from baseline to Day 4 and Day 30 were co-primary end points., Results: Increases in serum Na+ concentrations were significantly greater with tolvaptan than placebo at Day 4 (p = .0055) and at Day 30 (p < .0001). Two subjects receiving tolvaptan (28.6%) became dehydrated and experienced hypotension, and five subjects receiving placebo (41.7%) experienced symptoms associated with dilutional hyponatremia., Conclusions: These results suggest that tolvaptan effectively normalizes idiopathic hyponatremia in schizophrenic patients. Clinicians are advised to carefully monitor fluid status especially at the beginning of treatment to prevent dehydration.

Published
2008
Full Text
View/download PDF

23. Dexamethasone nonsuppression and short rapid eye movement latency in schizophrenia: markers of an affective diathesis?

Author

Goldman M, Tandon R, Taylor SF, DeQuardo JR, Shipley JE, Patel B, Reddig S, and Jibson M

Subjects
Adult, Biomarkers, Depressive Disorder genetics, Depressive Disorder physiopathology, Depressive Disorder psychology, Female, Humans, Hydrocortisone blood, Male, Polysomnography, Retrospective Studies, Risk Factors, Schizophrenia genetics, Schizophrenia physiopathology, Depressive Disorder diagnosis, Dexamethasone, Reaction Time physiology, Schizophrenia diagnosis, Schizophrenic Psychology, Sleep, REM physiology
Published
1996
Full Text
View/download PDF

26. Demeclocycline improves hyponatremia in chronic schizophrenics.

Author

Goldman MB and Luchins DJ

Subjects
Adult, Chronic Disease, Compulsive Behavior, Drinking Behavior, Female, Humans, Inappropriate ADH Syndrome complications, Male, Middle Aged, Demeclocycline therapeutic use, Hyponatremia drug therapy, Schizophrenia complications
Abstract

Serum sodium concentration increased significantly in eight hyponatremic schizophrenic subjects treated with demeclocycline. The incidence of severe hyponatremic episodes was significantly reduced. The authors argue that mild impairments in urinary dilution contribute to water intoxication in most chronic psychotics who develop this syndrome. Demeclocycline may help these patients.

Published
1985
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results